Compounds > 3-pyridyl pinacidil
Page last updated: 2024-11-06

3-pyridyl pinacidil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-pyridyl pinacidil: RN refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID43347
CHEMBL ID75172
SCHEMBL ID9456838
MeSH IDM0226154

Synonyms (10)

Synonym
ly-222675
CHEMBL75172
2-cyano-3-(3-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine
3-pyridyl pinacidil
guanidine, 2-cyano-3-(3-pyridyl)-1-(1,2,2-trimethylpropyl)-
1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-3-ylguanidine
SCHEMBL9456838
60560-07-8
DTXSID10975992
n''-cyano-n-(3,3-dimethylbutan-2-yl)-n'-pyridin-3-ylguanidine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID29396Ionisation constant (pKa2) due to proton loss from the pyridine ring1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID1148549Toxicity in po dosed mouse assessed as mortality after 7 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID1148550Hypotensive activity in po dosed spontaneously hypertensive Wistar-Okamoto rat assessed as dose required to cause 30 mmHg fall of blood pressure administered for 5 days1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
AID197347Concentration required to cause 15% increase in [86Rb+] efflux from rat portal vein.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID193409Maximum percent fall in Systolic blood pressure (SBP) was measured in anesthetized normotensive rat for 30 mins after intravenous (iv) injection at 0.03 mg/kg dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID190149The hypotensive activity expressed as rating of therapeutic index (MED/LD50 <1/200).1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Adaptive least-squares method applied to structure--activity correlation of hypotensive N-alkyl-N''-cyano-N'-pyridylguanidines.
AID193410Maximum percent fall in Systolic blood pressure (SBP) was measured in anesthetized normotensive rat for 30 mins after intravenous (iv) injection at 0.1 mg/kg dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID29374Ionisation constant (pKa1) due to protonation of the pyridyl ring1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID197525Concentration required to cause 50% inhibition of spontaneous activity in rat portal vein1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
AID197345Negative logarithm of the concentration causing a 100% inhibition of spontaneous mechanical activity in rat portal vein is determined in vitro1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
AID493017Wombat Data for BeliefDocking1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
5-hydroxydecanoate
5-hydroxydecanoic acid: Potassium Channel Blocker; RN refers to parent cpd		2.0110medium-chain fatty acid
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		1.9510azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
pinacidil
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)		3.2260pyridines
n'-cyano-n-(3-pyridyl)-n''-(t-butyl)guanidine
N'-cyano-N-(3-pyridyl)-N''-(t-butyl)guanidine: structure given in first source		2.6530
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine
N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener		2.6530pyridines
nicorandil
Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.		7.0110nitrate ester;
pyridinecarboxamide		potassium channel opener;
vasodilator agent
pinacidil pyridine n-oxide
pinacidil pyridine N-oxide: metabolite of pinacidil		1.9810
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		2.0110one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
clamikalant
clamikalant: inhibits ATP-sensitive potassium channel; structure in first source		2.0110
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		1.9810aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		02.3720
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.3720
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9810
Arrhythmia
[description not available]		02.0110
Injury, Myocardial Reperfusion
[description not available]		02.420
Heart Disease, Ischemic
[description not available]		02.0110
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		02.0110
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		07.0110
Cardiovascular Stroke
[description not available]		01.9810
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		01.9810